BioMarin to Report Q4 Earnings: Here's What to Expect

BioMarin Pharmaceutical (BMRN) is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16.67%.The Zacks Consensus Estimate for sales and earnings is pegged at $711.9 million and 73 cents per share, respectively, indicating a significant rise from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping BMRN’s Upcoming ResultsThough BioMarin’s portfolio comp ...